FULL-LENGTH TITLE : Pipeline for drug repurposing of FDA-approved drugs against SARS-CoV-1 and SARS-CoV-2 SHORT TITLE ( FOR THE RUNNING HEAD ) : Drug repurposing for COVID-19 AUTHOR NAMES :

AUTHOR AFFILIATIONS: Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique Hôpitaux de Marseille (AP-HM); Microbes, Evolution, Phylogeny and Infection (MEΦI); 2 Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France; Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, 13005 Marseille, France; 4 Aix Marseille Université, Laboratoire de Pharmacie Clinique, Marseille, France; 5 AP-HM, hôpital Timone, service pharmacie, Marseille, France ORCID ID : Sarah AHERFI : 0000-0002-5253-1757

[1]  Ruili Huang,et al.  Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics , 2020, Scientific Reports.

[2]  X. de Lamballerie,et al.  Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model , 2020, Nature Communications.

[3]  B. La Scola,et al.  In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2 , 2020, Molecules.

[4]  R. Schinazi,et al.  Repurposing Nucleoside Analogs for Human Coronaviruses , 2020, Antimicrobial Agents and Chemotherapy.

[5]  Jincun Zhao,et al.  Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models , 2020, bioRxiv.

[6]  B. La Scola,et al.  Methylene blue inhibits replication of SARS-CoV-2 in vitro , 2020, International Journal of Antimicrobial Agents.

[7]  S. Chanda,et al.  Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters , 2020, Research square.

[8]  R. Jordan,et al.  Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases , 2020, Proceedings of the National Academy of Sciences.

[9]  Hualiang Jiang,et al.  Structural basis for repurposing a 100-years-old drug suramin for treating COVID-19 , 2020, bioRxiv.

[10]  B. La Scola,et al.  GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition , 2020, bioRxiv.

[11]  H. Smyth,et al.  Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models , 2020, bioRxiv.

[12]  Collins Onyenaka,et al.  Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein’s Receptor Binding Domain and Recombinant Human ACE2 , 2020, bioRxiv.

[13]  B. La Scola,et al.  Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation , 2020, Travel Medicine and Infectious Disease.

[14]  N. Heaton,et al.  Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro , 2020, bioRxiv.

[15]  S. Lehrer,et al.  Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 , 2020, In Vivo.

[16]  C. Steppan,et al.  Comparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models , 2020, bioRxiv.

[17]  R. Schooley,et al.  Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity. , 2020, bioRxiv : the preprint server for biology.

[18]  P. Sharma,et al.  Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2 , 2020, International Journal of Biological Macromolecules.

[19]  Arun K. Ghosh,et al.  GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection , 2020, mBio.

[20]  Krystal L. Matthews,et al.  Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.

[21]  Catherine Z. Chen,et al.  Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 , 2020, bioRxiv.

[22]  L. Jeng,et al.  Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro , 2020 .

[23]  B. La Scola,et al.  Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate , 2020, International Journal of Infectious Diseases.

[24]  M. Amanlou,et al.  Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study , 2020, Life Sciences.

[25]  Carolina Q. Sacramento,et al.  Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production , 2020, Antimicrobial Agents and Chemotherapy.

[26]  A. N. El-hoshoudy.  Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation , 2020, Journal of Molecular Liquids.

[27]  Zhìhóng Hú,et al.  Anti-SARS-CoV-2 Potential of Artemisinins In Vitro , 2020, ACS infectious diseases.

[28]  F. Hussain,et al.  In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19. , 2020, Omics : a journal of integrative biology.

[29]  R. Jorge,et al.  In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.

[30]  Jin Il Kim,et al.  Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza , 2020, bioRxiv.

[31]  G. Whittaker,et al.  FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells , 2020 .

[32]  X. de Lamballerie,et al.  Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates , 2020, Nature.

[33]  M. Rosa-Calatrava,et al.  In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 , 2020, Antiviral Research.

[34]  Daniel J. B. Clarke,et al.  Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds , 2020, bioRxiv.

[35]  C. Rayner,et al.  Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro , 2020, bioRxiv.

[36]  Rafael V. C. Guido,et al.  Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19 , 2020, bioRxiv.

[37]  Sang Gu Kang,et al.  Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations , 2020, Life Sciences.

[38]  C. D. Dela Cruz,et al.  Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2 , 2020, bioRxiv.

[39]  R. Baric,et al.  Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.

[40]  P. German,et al.  Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects , 2020, Clinical and translational science.

[41]  R. Damoiseaux,et al.  Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication , 2020, bioRxiv.

[42]  H. Katoh,et al.  Antiviral activities of mycophenolic acid and IMD‐0354 against SARS‐CoV‐2 , 2020, Microbiology and immunology.

[43]  Xu Jia,et al.  SARS‐CoV‐2 and SARS‐CoV: Virtual screening of potential inhibitors targeting RNA‐dependent RNA polymerase activity (NSP12) , 2020, Journal of medical virology.

[44]  Andrew R. Leach,et al.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.

[45]  S. Cherry,et al.  Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2 , 2020, bioRxiv.

[46]  Sang Il Kim,et al.  Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19 , 2020, Scientific Reports.

[47]  P. Schultz,et al.  Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 , 2020, bioRxiv.

[48]  T. Seufferlein,et al.  Remdesivir but not famotidine inhibits SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids , 2020, bioRxiv.

[49]  M. Kiso,et al.  The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner , 2020, Viruses.

[50]  A. Geronikaki,et al.  In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus , 2020, Molecules.

[51]  Matthew J. O’Meara,et al.  Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 , 2020, bioRxiv.

[52]  Catherine Z. Chen,et al.  The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators , 2020, bioRxiv.

[53]  V. Thiel,et al.  Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2 , 2020, bioRxiv.

[54]  S. Graham,et al.  Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CLpro targeting repurposed drug candidates , 2020, Journal of Translational Medicine.

[55]  B. Coutard,et al.  Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase , 2020, bioRxiv.

[56]  B. Luan,et al.  In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease , 2020, The journal of physical chemistry letters.

[57]  Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal , 2020, International Journal of Antimicrobial Agents.

[58]  Seungtaek Kim,et al.  Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells , 2020, bioRxiv.

[59]  S. Krupanidhi,et al.  Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study , 2020, Informatics in Medicine Unlocked.

[60]  Milan Sencanski,et al.  Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method , 2020, Molecules.

[61]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[62]  J. E. Harti,et al.  Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis , 2020, Bioinformation.

[63]  Shufeng Liu,et al.  Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection , 2020, bioRxiv.

[64]  Xiaotao Lu,et al.  Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice , 2020, bioRxiv.

[65]  D. Raoult,et al.  In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect , 2020, Microbial Pathogenesis.

[66]  S. Jois,et al.  The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections , 2020, bioRxiv.

[67]  Peter G. Schultz,et al.  A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals , 2020, bioRxiv.

[68]  Sourav Das,et al.  An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study , 2020, Journal of biomolecular structure & dynamics.

[69]  P. Giavalisco,et al.  Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics , 2020, bioRxiv.

[70]  Kwang Su Kim,et al.  Multidrug treatment with nelfinavir and cepharanthine against COVID-19 , 2020, bioRxiv.

[71]  Joy Y. Feng,et al.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.

[72]  Hai-Feng Ji,et al.  A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease , 2020, Travel Medicine and Infectious Disease.

[73]  S. Matsuyama,et al.  Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro , 2020, bioRxiv.

[74]  Denisa Bojkova,et al.  Lack of antiviral activity of darunavir against SARS-CoV-2 , 2020, International Journal of Infectious Diseases.

[75]  Xiaotao Lu,et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice , 2020, Science Translational Medicine.

[76]  Bruno Coutard,et al.  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication , 2020, Scientific Reports.

[77]  Denisa Bojkova,et al.  SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles , 2020, bioRxiv.

[78]  Xuhui Huang,et al.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.

[79]  Jacques Fantini,et al.  Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.

[80]  Y. Yazdanpanah,et al.  Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia , 2020, bioRxiv.

[81]  A. Elfiky,et al.  Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study , 2020, Life Sciences.

[82]  David Shum,et al.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[83]  Yi Lu,et al.  In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy , 2020, Chinese Journal of Integrative Medicine.

[84]  Jinchao Yu,et al.  Network Bioinformatics Analysis Provides Insight into Drug Repurposing for COVID-2019 , 2020 .

[85]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[86]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  Y. Tong,et al.  Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model , 2020, Chinese medical journal.

[88]  M. Bjørås,et al.  Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19 , 2020, bioRxiv.

[89]  G. Peterson,et al.  Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses , 2020, Pharmaceuticals.

[90]  T. Pan,et al.  Teicoplanin potently blocks the cell entry of 2019-nCoV , 2020, medRxiv.

[91]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[92]  Bo Zhang,et al.  Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture , 2020, Emerging microbes & infections.

[93]  O. Bolaji,et al.  Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach , 2019, Current therapeutic research, clinical and experimental.

[94]  Joy Y. Feng,et al.  Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir , 2019, Viruses.

[95]  G. Boivin,et al.  Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures , 2018, bioRxiv.

[96]  Chiou-Feng Lin,et al.  The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR , 2018, PLoS neglected tropical diseases.

[97]  Emily M. Lee,et al.  Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry , 2018, Cell Discovery.

[98]  Xiaotao Lu,et al.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.

[99]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[100]  D. Oupický,et al.  Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies. , 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[101]  D. Smee,et al.  Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties. , 2017, Journal of virological methods.

[102]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[103]  M. Frieman,et al.  Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion , 2016, Journal of Virology.

[104]  T. Pan,et al.  Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) , 2016, The Journal of Biological Chemistry.

[105]  K. Rainsford,et al.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases , 2015, Inflammopharmacology.

[106]  C. A. Morris,et al.  Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[107]  J. Rossignol.  Nitazoxanide: A first-in-class broad-spectrum antiviral agent , 2014, Antiviral Research.

[108]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[109]  T. Bestebroer,et al.  Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.

[110]  Christian Drosten,et al.  Targeting Membrane-Bound Viral RNA Synthesis Reveals Potent Inhibition of Diverse Coronaviruses Including the Middle East Respiratory Syndrome Virus , 2014, PLoS pathogens.

[111]  W. Wernsdorfer,et al.  Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses , 2013, Malaria Journal.

[112]  Sarah Hunt.  Review 2 , 2012 .

[113]  Olga Vasiljeva,et al.  Cysteine cathepsins: From structure, function and regulation to new frontiers , 2011, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics.

[114]  M. G. L. Parra,et al.  Bioavailability of Two Oral-Suspension Formulations of a Single Dose of Nitazoxanide 500 mg: An Open-Label, Randomized-Sequence, Two-Period Crossover, Comparison in Healthy Fasted Mexican Adult Volunteers , 2011 .

[115]  O. Bakare,et al.  Biological Activities of Emetine , 2011 .

[116]  S. H. Park,et al.  Absorption, Distribution, Excretion, and Pharmacokinetics of 14C-Pyronaridine Tetraphosphate in Male and Female Sprague-Dawley Rats , 2010, Journal of biomedicine & biotechnology.

[117]  R. Baric,et al.  A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo , 2009, Virology.

[118]  P. Olliaro,et al.  Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers , 2009, European Journal of Clinical Pharmacology.

[119]  J. Chu,et al.  Antiviral Activity of Emetine Dihydrochloride Against Dengue Virus Infection , 2009 .

[120]  D. Smee,et al.  Identification of Novel Antipoxviral Agents: Mitoxantrone Inhibits Vaccinia Virus Replication by Blocking Virion Assembly , 2007, Journal of Virology.

[121]  Po-Huang Liang,et al.  Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. , 2007, Journal of medicinal chemistry.

[122]  D. Barnard,et al.  Evaluation of Immunomodulators, Interferons and Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice , 2006, Antiviral chemistry & chemotherapy.

[123]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[124]  T. Mizutani,et al.  Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus , 2005, Antiviral Research.

[125]  Jindrich Cinatl,et al.  Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines , 2004, Biochemical and Biophysical Research Communications.

[126]  Marc Van Ranst,et al.  In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine , 2004, Biochemical and Biophysical Research Communications.

[127]  H. Hsieh,et al.  Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide , 2004, Antimicrobial Agents and Chemotherapy.

[128]  Y. Guan,et al.  In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds , 2004, Journal of Clinical Virology.

[129]  Jindrich Cinatl,et al.  HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.

[130]  M. Otto,et al.  Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N4-Hydroxycytidine , 2004, Antiviral chemistry & chemotherapy.

[131]  H. Doerr,et al.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.

[132]  P. Newton,et al.  A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. , 2001, British journal of clinical pharmacology.

[133]  T. Q. Binh,et al.  A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. , 1998, British journal of clinical pharmacology.

[134]  Dirk C. Mattfeld,et al.  A Computational Study , 1996 .

[135]  B. Levine,et al.  Mefloquine distribution in postmortem cases. , 1994, Forensic science international.

[136]  A. Breckenridge,et al.  Tissue Distribution and Excretion of Amodiaquine in the Rat , 1988, The Journal of pharmacy and pharmacology.

[137]  R. Minchin,et al.  Comparative uptake of quinine and quinidine in rat lung , 1981, The Journal of pharmacy and pharmacology.

[138]  P. Welling,et al.  Protein Binding of Antimicrobials: Clinical Pharmacokinetic and Therapeutic Implications , 1977, Clinical pharmacokinetics.

[139]  P. Welling,et al.  Bioavailability of Tetracycline and Doxycycline in Fasted and Nonfasted Subjects , 1977, Antimicrobial Agents and Chemotherapy.

[140]  A. J. Popert.  Chloroquine: a review. , 1976, Rheumatology and rehabilitation.

[141]  M. Rudhardt,et al.  Behaviour of doxycycline in the tissues. , 1975, Chemotherapy.

[142]  E. C. Weinbach,et al.  Mechanism of Action of Reagents that uncouple Oxidative Phosphorylation , 1969, Nature.